First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the first patient has been dosed in its Phase I study comparing the profiles of intramuscular (“IM”) and intravenous (“IV”)…


The product has been added to your cart.

Continue shopping View Cart